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Osteoarthritis (OA), the most common form of arthritis, is
a public health problem throughout the world. The preva-
lence of OA of the knee in Western Europe has been esti-
mated as 18e25% in men and 24e40% in women
between ages 60e79 in Holland1 and 28e34% in Spain2.
There are estimates of 100 million people with OA in the
European Union. The estimated direct cost of OA in France
in 2001 was 1.64 Billion Euros3. In the United States, the
burden of arthritis is 69.9 Million people in 20014,5.
Guidelines
Therapeutic guidelines for OA of the knee have been de-
veloped by several groups, including the American College
of Rheumatology (ACR)6,7 and a Task Force of the Stand-
ing Committee for International Clinical Studies Including
Therapeutic Trials (ESCISIT) of the European League
Against Rheumatism (EULAR)8. The EULAR objectives
include to (1) educate the patient about OA and its manage-
ment, (2) alleviate pain, (3) improve function and decrease
disability, and (4) prevent or retard progression of the
disease and its consequences.
The EULAR recommendations graded the level of evi-
dence where publications exist. The ACR guidelines were
developed in 1996 and modiﬁed in 2000. Each of the ther-
apies for OA was discussed with supporting evidence of
use. Though derived by different mechanisms, there are
strong similarities with relatively minor differences between
the EULAR and ACR guidelines. Some of the differences
are reﬂected in the directions of the regulatory agencies
and in clinical use of medications. However, despite the
similarities of guidelines, signiﬁcant differences exist among
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steroidal antiinﬂammatory drugs (NSAIDs), cyclooxygenase
(COX)-2 selective inhibitors and analgesics for the treat-
ment of pain9.
In relation to the regulatory agencies, the European
Agency for the Evaluation of Medicinal Products (EMEA)
has placed strong restrictions on the use of COX-2 agents,
with no restrictions on non-selective NSAIDs, while the
United States Food and Drug Administration (FDA) has
placed ‘‘black box’’ warnings on all NSAIDs, both selective
and non-selective. Neither the guidelines nor the regulatory
agencies recognize any agent as a structure (disease)
modifying agent. However, the EULAR guidelines assign
to glucosamine sulfate a ranking of ‘‘highest level of
evidence and strength of recommendation’’ based on ran-
domized clinical trials, for its use as a symptom-modifying
drug in knee OA. Indeed, in continental Europe glucosamine
sulfate is a prescription drug, which may in part explain the
difference with the ACR guidelines wherein glucosamine in
a variety of formulations is considered a dietary supplement.
Symptomatic beneﬁt of glucosamine
Despite multiple double-blind, controlled clinical trials on
the use of glucosamine in OA of the knee, controversy
on efﬁcacy related to symptomatic improvement continues.
Indeed, meta-analyses have produced conﬂicting resul-
ts10e12. In the Cochrane Review, it is suggested that con-
ﬂicting trial results might be due to the use of different
formulations of glucosamine, with the most favorable trial
results being associated with the prescription glucosamine
sulfate preparation, nevertheless, the controversy con-
tinues. Two recently presented studies, as follows, add
further information regarding its clinical status.
A National Institutes of Heath sponsored study labeled
the Glucosamine/chondroitin Arthritis Intervention Trial
(GAIT), examined placebo vs glucosamine hydrochloride
(500 mg three times daily) vs chondroitin sulfate (400 mg63
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chondroitin vs celecoxib (200 mg/day) in a parallel, blinded
6 month multicenter study of response in knee OA13. The
primary efﬁcacy variable was a 20% improvement in knee
pain from baseline to 24 weeks. When compared to pla-
cebo, there was a 10% greater number of subjects meeting
the primary efﬁcacy variable in the celecoxib group
(P¼ 0.008) with no signiﬁcant differences in the other ther-
apeutic subsets. There was a trend for a difference between
the combination glucosamine/chondroitin vs placebo
(P¼ 0.09); this difference was greater in a pre-determined
analysis using the Outcome Measures in Rheumatology
(OMERACT)eOsteoarthritis Research Society International
(OARSI) responder criteria (P¼ 0.02)14, but did not reach
signiﬁcance at the prespeciﬁed criterion of P less than
0.017 required for multiple comparisons. In an exploratory
analysis of a subset of individuals with higher pain levels
at baseline, however, the response of pain to the
combination was highly signiﬁcant (P¼ 0.002).
The Glucosamine Unum In Die [Once-a-day] Efﬁcacy
(GUIDE) trial15, a 6-month double-blind, multicenter trial in
Spain and Portugal examining placebo vs crystalline
glucosamine sulfate (1500 mg once daily) vs acetamino-
phen (3000 mg/day) has also recently been presented.
The primary efﬁcacy variable was a change in the Lequesne
algofunctional index. Although there was a numeric differ-
ence in improvement in the Lequesne algofunctional index
between acetaminophen and placebo, only the improve-
ment in the Lequesne algofunctional index for glucosamine
sulfate vs placebo was signiﬁcant (P¼ 0.032). Secondary
analyses, including the OARSI responder indices were
signiﬁcant for glucosamine (P¼ 0.004).
Structure modiﬁcation
There are two double-blind 3-year trials that examined
glucosamine sulfate in OA of the knee measuring the radio-
graphic joint space from standing knee posterioreanterior
radiographs16,17. The studies had similar design. When
comparing the placebo to glucosamine sulfate, change in
minimum joint space width (JSW) was less in the glucos-
amine groups (Belgium study: P¼ 0.003 and Prague study:
P¼ 0.001). In a 5 year followup of the Belgium study, the
relative risk of those who were taking glucosamine during
the trial vs the control population that went on to undergo
lower limb OA related surgery during followup was 0.52
(P¼ 0.06), even though small numbers were involved18.
Kaplan Meier Survival analysis for total knee prosthesis
was signiﬁcant for those taking glucosamine sulfate
(P¼ 0.023). In a 5 year followup of the Prague study, there
was a 73% reduction in knee replacement surgery for those
who had been on glucosamine vs the control group
(P¼ 0.021)19. In the above trials, JSW was assessed using
standing anteroposterior knee radiographs. This has
created controversy with contrasting studies: one reported
that change in knee pain may affect measurement of
JSW20; the other did not ﬁnd pain as a confounder of JSW
in the Belgium and Prague studies.21.
The GAIT includes a subset being examined for structure
modiﬁcation. This 24-month portion of the study is pending
completion and analysis. The GAIT will add to our knowl-
edge of glucosamine hydrochloride and/or chondroitin
sulfate use for structure modiﬁcation in OA of the knee. Un-
fortunately, the GAIT did not address glucosamine sulfate
and the difference in efﬁcacy between glucosamine hydro-
chloride and glucosamine sulfate is unknown.Glucosamine pharmacology
Single dose studies of glucosamine suggest that the serum
level of glucosamine distributed in the tissue is below that
needed to stimulate cellular activity22,23. One study found
glucosamineplasma levels ashighas11.5 mMafter ingestion
of 1500 mgglucosamine sulfate in patientswith localizedOA,
but was not able to ﬁnd similar levels in all subjects22.
However, glucosamine is readily absorbed from the gastroin-
testinal tract, with steady state achieved in 3 days of oral
administration of glucosamine sulfate 1500 mg once-a-day,
andaveragepeakplasma levels in the10 mMrange inhealthy
subjects24. Although a study in horses found a 10-fold differ-
ence between serum and synovial ﬂuid concentrations of
glucosamine after a single nasogastric administration of glu-
cosamine hydrochloride, similar peak plasma and synovial
ﬂuid concentrations could be detected at steady state in pa-
tients with knee OA after repeated dosing with glucosamine
sulfate 1500 mg once daily25. In a human chondrocyte cell
model26, glucosamine sulfate resulted in a decrease in
IL-1b-stimulated gene expression of all markers examined,
with glucosamine inhibitory concentration (IC) 50 close to
10 mM or slightly lower; of note, this corresponds to the con-
centrations found inhumanplasmaandsynovial ﬂuidafterad-
ministration of the 1500 mg once daily formulation of
crystalline glucosamine sulfate used in the European tri-
als24,25. Conversely, a pharmacokinetic study evaluating glu-
cosaminehydrochloride1500 mgdailyasused inGAIT found
peak glucosamine plasma levels of 3 mM which might not
reach the threshold for a pharmacological effect27.
Some evidence indicates glucosamine inhibits Interleukin
(IL)-1 intracellular signaling cascade and gene expression
as the possible mechanism of action in OA. In vitro, glucos-
amine sulfate has been demonstrated to reduce prostaglan-
din E2 (PGE2) production and interfere with nuclear factor
kappa B (NFkB) DNA binding in chondrocytes and synovial
cells28,29. Some studies on mechanism have investigated
higher glucosamine concentrations than those found clini-
cally in human plasma and synovial ﬂuid of patients ingest-
ing glucosamine 1500 mg daily; further studies would be of
value to validate whether these effects can be achieved at
the 10 mM concentrations26. Otherwise, it has been specu-
lated that glucosamine might have effects on organs or tis-
sues different from the joint and cartilage22,23.
Glucosamine inhibits gene expression of OA cartilage
in vitro30. It was suggested that since glucosamine inhibits
both anabolic and catabolic genes, the therapeutic effects
of glucosamine might be due to anti-catabolic activities,
rather than due to anabolic activities. The authors point
out that glucosamine sulfate is a stronger inhibitor of gene
expression than glucosamine hydrochloride.
Comparison of recent studies
There are several potential confounders that may have
relevance when trying to interpret the seemingly contradic-
tory results of the clinical trials, such as the GAIT and
GUIDE.
In North America, glucosamine hydrochloride or sulfate
and chondroitin sulfate are considered nutraceuticals,
whereas in most European countries these are marketed
as pharmaceuticals. Therefore, production and marketing
of glucosamine are more closely monitored in Europe. In
North America, varying quantities of glucosamine have
been noted in a survey of several nutraceuticals31.
Most of the negative clinical trials were performed with
glucosamine hydrochloride 500 mg three times daily,
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glucosamine sulfate powder for oral solution at the dose of
1500 mg once daily. In addition, although the sulfate is read-
ily hydrolyzed from the glucosamine in the gastrointestinal
tract, there are suggestions that sulfate is in itself
clinically relevant32,33. Serum sulfate concentration signiﬁ-
cantly increases after ingestion of 1 g of glucosamine
sulfate, but not with sodium sulfate. Sufﬁcient sulfur is
essential for the synthesis of proteoglycans and other
S-containing metabolic intermediates (coenzyme A, gluta-
thione, etc.), important for chondrocyte metabolism.
Interestingly, the most clinically relevant results in GAIT
were seen when sodium chondroitin sulfate was taken
with glucosamine hydrochloride; whether this may be
explained by an increase in the bioavailablity of sulfates33
together with glucosamine requires further study. It is of
note that several of the glucosamine preparations contain
other salts that could potentially inﬂuence uptake and
utilization of glucosamine23.
There are differences in the study populations between
the European and North American continents. As in many
OA studies, the North American study groups tended to
weigh more . For example, the BMI (body mass index) for
the GAIT was 31.7 and the BMI for the GUIDE study was
27.7. Although of unknown signiﬁcance, the genetic and eth-
nic backgrounds of the study population were also different.
Additional differences in study populations between GAIT
and GUIDE are the level of pain upon entry and the placebo
response rate. Upon entry, the GAIT pain was 47.2 on the
Western Ontaria McMasters University Osteoarthritis index
(WOMAC) (normalized 100 mm scale), while the GUIDE
study had 39.5 pain upon entry.
The placebo response for many clinical trials with oral
agents in treatment of knee OA has traditionally been
around 30%14 and these usual ﬁgures were replicated in
the GUIDE study. The high placebo response in the GAIT
(60.1%) is of unknown signiﬁcance.
Rescue analgesic medications are now used in nearly all
trials of over 6 weeks. There is some question if the use of
acetaminophen, ibuprofen or other analgesics makes these
trials comparison trials rather than placebo controlled trials.
The GAIT allowed subjects to use acetaminophen 500 mg
tablet up to 4 g daily as rescue analagesia. They averaged
1.2e1.9 tablets per day. The GUIDE trial used ibuprofen
escape analgesia under protocol-speciﬁed strict rules for
use, that decreased the utilization of the rescue, averaging
only 0.20e0.26 tablets of 400 mg ibuprofen per day.
It is of note that the increases in serum sulfate from
glucosamine sulfate were reversed when 1 g acetamino-
phen was ingested at the same time, presumably due to
the formation of sulfateeacetaminophen metabolites that
are excreted in the bile and urine33.
The overall completion rate in the GAIT was 79.5%
similar to the GUIDE completion rate of 72%.
The instruments used in OA trials have varied. Indeed,
the GAIT used a summary WOMAC, whereas the GUIDE
trial used the Lequesne algofunctional index as the primary
measured variable.
From these studies we have learned that OA of the knee
continues to be difﬁcult to study and that our instruments
that measure change are good, but could be better. Indeed,
what seems to be minor differences in protocols often
results in differing and confusing information.
Although there has been a public comment that the differ-
ences in the trials are due to corporate vs non-corporate
sponsorship, there have been no data produced to support
such allegation. Indeed, one could argue that the differencesin results were more from the differences in product, study
design and study populations. Although, unfortunately, the
controversy continues, symptomatic efﬁcacy described in
multiple studies performed with glucosamine sulfate support
continued consideration in the OA therapeutic armamentar-
ium. Further studies, particularly addressing efﬁcacy at
higher pain levels, will help in additionally deﬁning their utility
in the OA treatment paradigm.
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